Edwards(US:EW) ZACKS·2025-04-23 23:00Core Insights - Edwards Lifesciences reported revenue of $1.41 billion for the quarter ended March 2025, reflecting an 11.6% decline year-over-year, with EPS at $0.64 compared to $0.66 in the previous year [1] - The revenue exceeded the Zacks Consensus Estimate of $1.4 billion by 0.71%, while the EPS surpassed the consensus estimate of $0.60 by 6.67% [1] Revenue Performance - Net Sales in Europe were $341.80 million, below the average estimate of $357.01 million, marking a 7.1% decrease year-over-year [4] - Net Sales outside the United States reached $573.80 million, slightly above the estimated $573.77 million, but down 12.7% from the previous year [4] - Net Sales in the United States totaled $838.90 million, below the average estimate of $849.03 million, representing a 10.8% decline year-over-year [4] - Net Sales in Japan were $81.80 million, significantly lower than the estimated $96.40 million, indicating a 26.2% decrease [4] - Net Sales in the Rest of the World amounted to $150.20 million, exceeding the estimate of $120.36 million, but down 16% year-over-year [4] Product Group Performance - Transcatheter Aortic Valve Replacement generated $1.05 billion, surpassing the average estimate of $1.03 billion, with a year-over-year increase of 3.8% [4] - Surgical Structural Heart sales were $250.90 million, slightly below the estimated $254.51 million, reflecting a 5.7% decline year-over-year [4] - Transcatheter Mitral and Tricuspid Therapies achieved $115.20 million, exceeding the average estimate of $113.82 million, with a substantial year-over-year increase of 58% [4] Stock Performance - Shares of Edwards Lifesciences have returned -0.9% over the past month, compared to a -6.6% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]